Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers

Talar Tokatlian(Massachusetts Institute of Technology), Benjamin J. Read(Harvard University), Christopher A. Jones(Massachusetts Institute of Technology), Daniel W. Kulp(The Wistar Institute), Sergey Menis(Scripps Research Institute), Jason Y.H. Chang(Massachusetts Institute of Technology), Jon M. Steichen(Scripps Research Institute), Sudha Kumari(Massachusetts Institute of Technology), Joel D. Allen(University of Southampton), Eric L. Dane(Massachusetts Institute of Technology), Alessia Liguori(Scripps Research Institute), Maya Sangesland(Ragon Institute of MGH, MIT and Harvard), Daniel Lingwood(Ragon Institute of MGH, MIT and Harvard), Max Crispin(Scripps Research Institute), William R. Schief(Scripps Research Institute), Darrell J. Irvine(Scripps Research Institute)
Science
December 20, 2018
Cited by 311Open Access
Full Text

Abstract

In vaccine design, antigens are often arrayed in a multivalent nanoparticle form, but in vivo mechanisms underlying the enhanced immunity elicited by such vaccines remain poorly understood. We compared the fates of two different heavily glycosylated HIV antigens, a gp120-derived mini-protein and a large, stabilized envelope trimer, in protein nanoparticle or "free" forms after primary immunization. Unlike monomeric antigens, nanoparticles were rapidly shuttled to the follicular dendritic cell (FDC) network and then concentrated in germinal centers in a complement-, mannose-binding lectin (MBL)-, and immunogen glycan-dependent manner. Loss of FDC localization in MBL-deficient mice or via immunogen deglycosylation significantly affected antibody responses. These findings identify an innate immune-mediated recognition pathway promoting antibody responses to particulate antigens, with broad implications for humoral immunity and vaccine design.


Related Papers

No related papers found

Powered by citation graph analysis